| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Indivior Pharmaceuticals, Inc.$40.5
-0.86 (-2.08%)
C 54Pipeline Score Fair Value Pharma · Commercial
Market Cap
4.58 B
EPS
2.01
P/E Ratio
19.01 $
Value Trade
52.95 M
SEC Financials
Q1 2026Dilution Risk
Revenue
317.00 M
R&D Expenses
16.00 M
Operating CF
-9.00 M
Total Assets
1.20 B
Total Liabilities
1.34 B
Equity
-144.00 M
D/E Ratio
12,345
0.05 %
Week
15.55 %
1 Month
8.44 %
3 Month
18.88 %
6 Month
249.12 %
5 Year
247.5 %
All Time
Cash Data
Cash Position
175.00 M
Monthly Burn
3.00 M
Runway
56.2 mo
Burn Trend
SEC Filing
Apr 30, 2026
Overview
Volume
1.26 M
52 Week Range
11.49 - 41
% held by Insiders
10.15 %
% held by Institutions
96.05 %
Enterprise Value
4.91 B
Total Shares
121.97 M
Short %
9.5 %
Float Shares
113.44 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Indivior Pharmaceuticals, Inc.
271Total events
1Upcoming
100Tier-1 (high impact)
2015 – 2026Coverage
Upcoming catalysts 1
Event history 270
Q3 2026
◆Timing GuidancePresentation
On track to enter Phase III of Indivior Action Agenda – Breakout – in second half of 2026
May 20, 2026
▲Full ResultsSUBLOCADEApprovedClinical Data
Two real-world evidence studies published showing adherence to SUBLOCADE associated with lower relapse risk and reduced healthcare utilization
opioid use disordersource ↗
Apr 30, 2026
▼Program DiscontinuationINDV-6001DiscontinuedCorporate
Indivior will not pursue Phase 3 development of INDV-6001; amended license with Alar Pharmaceuticals
opioid use disordersource ↗
Apr 30, 2026
▼Primary Endpoint MissedINDV-2000DiscontinuedClinical Data
INDV-2000 (Rocavorexant) did not meet primary endpoint of 'no treatment failure' in Phase 2 POC study
opioid use disordersource ↗
Apr 30, 2026
▼Program DiscontinuationINDV-2000DiscontinuedCorporate
Indivior will not advance INDV-2000 internally
opioid use disordersource ↗
Mar 31, 2026
▲PublicationSUBLOCADEApprovedPresentation
Cost impact model published in The Journal of Current Medical Research and Opinion
opioid use disordersource ↗
Mar 17, 2026
Mar 12, 2026
Feb 26, 2026
Drug Pipeline Intelligence
C54
Pipeline Score $1.8B
Pipeline ValueFair Value
Valuation Signal15
Drugs Scored1.3x
rNPV / MCap Top 82%
Small Cap (rank 165 of 911)
Percentile RankIndivior Pharmaceuticals, Inc. carries a moderate pipeline score (54/100), with $5.7B risk-adjusted pipeline value, led by XP19986 in GERD (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| XP19986 Small molecule | GERD | Phase 2 | NCT00838396 | 31% | $966M | COMPLETED | 58 | - | - | Aug 1, 2006 | - | Sep 14, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SUBLOCADE Priority | opioid use disorder | — | 2025-12-17 | more than 43 instances per week at screening to fewer than three instances per week by week three; higher opioid abstinence rates with 300-mg dose compared to 100 mg Read More | New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations Read More | |
SUBLOCADE Priority | opioid use disorder | — | 2025-12-17 | more than 43 instances per week at screening to fewer than three instances per week by week three; higher opioid abstinence rates with 300-mg dose compared to 100 mg Read More | New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations Read More | |
SUBLOCADE Priority | opioid use disorder | — | 2025-12-17 | more than 43 instances per week at screening to fewer than three instances per week by week three; higher opioid abstinence rates with 300-mg dose compared to 100 mg Read More | New Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INDV
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INDV Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INDVNew Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
Indivior Pharmaceuticals announced findings from two studies indicating that adherence to monthly injectable buprenorphine is linked to lower relapse rates and reduced healthcare utilization among individuals with opioid use disorder. The studies revealed that patients using this treatment had significantly fewer infections and hospital visits compared to those on daily oral buprenorphine. These results underscore the importance of sustained treatment in managing opioid use disorder effectively.
Read more →INDVIndivior Announces $175 Million Accelerated Share Repurchase
Indivior Pharmaceuticals has announced a $175 million accelerated share repurchase agreement with Barclays Bank. This move is part of a larger $400 million share repurchase program, showcasing the company's confidence in its financial health and strategic direction. The ASR is expected to result in the repurchase of approximately 3.7 million shares, with final settlement anticipated by the end of June 2026.
Read more →INDV▲ +7.7%on this newsshared move
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
Indivior Pharmaceuticals reported a strong financial performance for Q1 2026, with total net revenue reaching $317 million, a 19% increase year-over-year. The company raised its full-year guidance, driven by a 32% growth in SUBLOCADE net revenue. However, it announced the discontinuation of Phase 3 development for INDV-6001 and will not advance INDV-2000 internally. The company remains focused on enhancing shareholder value through strategic capital deployment.
Read more →INDVIndivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th
Indivior Pharmaceuticals, Inc. will report its first quarter 2026 financial results on April 30, 2026. Following the report, CEO Joe Ciaffoni and the leadership team will host a live webcast at 8:00 a.m. U.S. EDT. The event will be accessible via the company's website, promoting transparency with investors.
Read more →INDV▲ +5.9%on this news
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
Indivior Pharmaceuticals has published a cost impact model indicating that SUBLOCADE, a monthly injectable buprenorphine, may significantly reduce staffing needs and associated costs in correctional facilities compared to other opioid use disorder treatments. The model estimates substantial savings and highlights the potential for improved operational efficiency in jails and prisons. However, the study has limitations, including the exclusion of medication acquisition costs.
Read more →INDVNational Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder
A recent survey by Indivior reveals that only 58% of U.S. correctional facilities provide medications for opioid use disorder (MOUD), with significant regional disparities. Jails are more likely to offer MOUD than prisons, and facilities in the South report the lowest access rates. The study emphasizes the need for improved continuity of care and support systems for individuals with opioid use disorder post-incarceration.
Read more →INDVIndivior Prices Upsized $450.0 Million Convertible Senior Notes Offering - March 12, 2026
Indivior Pharmaceuticals announced the pricing of its upsized $450 million convertible senior notes offering, which is expected to close on March 17, 2026. The notes will accrue interest at 0.625% and mature in 2031, with specific conditions for conversion. The proceeds will be used for debt repayment, share repurchases, and general corporate purposes.
Read more →INDVIndivior Reports Fourth Quarter and Full-Year 2025 Financial Results
Indivior Pharmaceuticals reported strong financial results for Q4 and full year 2025, highlighting a 13% increase in SUBLOCADE net revenue and a 20% rise in adjusted EBITDA. The company is now executing Phase II of its Action Agenda, focusing on accelerating growth and enhancing cash flow in 2026. Strategic capital deployment plans include managing debt and a new share repurchase program.
Read more →INDVIndivior Reports Fourth Quarter and Full-Year 2025 Financial Results
Indivior Pharmaceuticals reported strong financial results for Q4 and full-year 2025, highlighting a 13% increase in SUBLOCADE net revenue and a 20% rise in adjusted EBITDA. The company is now executing Phase II of its Action Agenda, aiming to accelerate growth and cash flow in 2026. Indivior also completed its corporate domicile change to the U.S., enhancing its operational focus.
Read more →INDVIndivior to Participate in Upcoming Investor Conferences
Indivior Pharmaceuticals has announced its participation in upcoming investor conferences. The company, a leader in treatments for opioid use disorder, aims to advance the understanding of this chronic condition. Indivior is committed to delivering evidence-based treatment and supporting individuals in their recovery journey.
Read more →INDVIndivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
Indivior Pharmaceuticals announced it will report its fourth quarter and full-year 2025 financial results on February 26, 2026. Following the results, a live webcast presentation will be held featuring CEO Joe Ciaffoni and other leadership team members. The event aims to provide insights into the company’s performance and future direction.
Read more →INDVIndivior Announces Completion of Redomiciliation to the United States
Indivior Pharmaceuticals has successfully completed its redomiciliation from the UK to the US, establishing a new parent company, Indivior Pharmaceuticals, Inc. The transition, approved by shareholders, aims to leverage the benefits of a U.S. stock listing. The company anticipates improved corporate governance and enhanced collaboration in addressing opioid use disorder.
Read more →INDVFIRST AMENDMENT TO NOTE PURCHASE AGREEMENT THIS FIRST AMENDMENT TO NOTE PURCHASE AGREEMENT , dated as of
Indivior PLC has announced a first amendment to its note purchase agreement, facilitating the transition to U.S. corporate domicile. This amendment includes a change of control where Indivior Pharmaceuticals, Inc. will become the parent company of Indivior PLC. The amendment will allow financial statements to be reported under the new corporate structure of TopCo and its subsidiaries. Once effective, this change will lead to Indivior UK becoming a wholly-owned subsidiary of Indivior U.S.
Read more →INDVIndivior Provides Full-Year 2026 Financial Guidance and Business Update Total Net Revenue Expected in the Range of $1,125 million to $1,195 million Total SUBLOCADE Net Revenue Expected to be in the Range of $905 million
Indivior PLC has released its financial guidance for the year 2026, projecting total net revenue between $1,125 million and $1,195 million. The company anticipates SUBLOCADE net revenue will range from $905 million to $945 million, reflecting an expected growth of 11% in dispense units. Additionally, adjusted EBITDA is forecasted to increase significantly by 35%, demonstrating a positive trajectory for the company after a transitional year in 2025. With this guidance, Indivior aims to accelerate its growth and optimize its operating model.
Read more →INDVIndivior Announces Inclusion in the S&P SmallCap 600® Index
Indivior PLC has announced its inclusion in the S&P SmallCap 600 index, effective immediately. This milestone is seen as a significant enhancement to the company's presence in capital markets. CEO Joe Ciaffoni emphasized the commitment to expanding their leading treatment, SUBLOCADE, for opioid use disorder as part of their new operating model.
Read more →INDVNew Study Shows Extended-Release Buprenorphine Safely Delivers Rapid, Clinically Meaningful Reductions in Opioid Use and Supports Abstinence in High-Risk Populations
Indivior PLC announced positive results from a clinical trial of SUBLOCADE, an extended-release buprenorphine treatment for opioid use disorder. The study demonstrated that both 100-mg and 300-mg doses significantly reduced opioid use and improved abstinence rates. Notably, the higher dose was particularly effective for individuals with high-frequency fentanyl use, although injection-site reactions were more frequent in this group.
Read more →INDVIndivior Concludes Legacy U.S. Department of Justice Matter
Indivior PLC has concluded its legacy matter with the U.S. Department of Justice by paying $295 million. This payment, made from the company's cash reserves, terminates the resolution agreement with the DOJ. CEO Joe Ciaffoni expressed satisfaction with this milestone, highlighting its positive impact on the company's liability and capital structure.
Read more →INDVIndivior to Participate in the Piper Sandler 37th Annual Healthcare Conference
Indivior PLC has announced its participation in the Piper Sandler 37th Annual Healthcare Conference. The company aims to transform opioid use disorder from a crisis to a recognized chronic disease through evidence-based treatments. Indivior continues to build its pipeline of product candidates to enhance its offerings in this area.
Read more →INDVTHIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. PART II OF THIS DOCUMENT COMPRISES AN EXPLANATORY STATEMENT IN COMPLIANCE WITH SECTION 897 OF THE COMPANIES ACT 2006 . If you are in any doubt as to the c
Indivior has issued an important document requiring immediate attention from its shareholders regarding a proposed Scheme of Arrangement under the Companies Act 2006. This document includes calls for action from shareholders, along with details about upcoming meetings for voting. It emphasizes that the document is not an offer to purchase shares and cautions that restrictions may exist for distribution in certain jurisdictions. Shareholders are advised to read the document thoroughly and ensure compliance with the voting instructions provided.
Read more →INDV▲ +6.2%on this news
Indivior Presents New Real-World Evidence at AMCP Nexus 2025 Demonstrating Clinical and Economic Benefits of Adherence to Monthly Injectable Buprenorphine
Indivior presented new findings at the AMCP Nexus 2025 conference, demonstrating the clinical and economic benefits of monthly injectable buprenorphine (SUBLOCADE) for treating opioid use disorder (OUD). The data indicates that higher adherence to SUBLOCADE leads to reduced healthcare resource utilization and improved patient outcomes. However, the study has limitations due to its retrospective nature and potential biases.
Read more →INDV▲ +15.4%on this news· ran to +27% by day 3shared move
Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance
Indivior PLC reported its financial results for Q3 2025, highlighting significant growth in SUBLOCADE revenue and an increase in full-year financial guidance. The company is transitioning to Phase II of its Action Agenda, which aims to enhance profitability and cash generation. CEO Joe Ciaffoni emphasized the successful execution of their business strategy, which includes operational simplifications.
Read more →INDVIndivior to Participate in the Stifel 2025 Healthcare Conference
Indivior PLC announced its participation in the Stifel 2025 Healthcare Conference. The company is dedicated to developing treatments for opioid use disorder (OUD) and aims to transform OUD into a recognized chronic disease. Indivior continues to build its portfolio and pipeline of product candidates in this area.
Read more →INDVIndivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th
Indivior PLC has announced it will report its third quarter 2025 financial results on October 30, 2025. Following the results, CEO Joe Ciaffoni and the leadership team will host a live webcast presentation. The event aims to keep investors informed about the company's financial performance and ongoing commitment to treating opioid use disorder.
Read more →INDVClinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment
Indivior PLC has published positive results from a clinical trial demonstrating that rapid induction with SUBLOCADE® leads to higher retention rates in patients with opioid use disorder compared to standard induction. The study found that administering a single dose of oral buprenorphine followed by a SUBLOCADE injection on the same day was well tolerated, particularly among fentanyl-positive participants. This approach may enhance patient engagement during the critical early weeks of treatment.
Read more →INDVIndivior Proposes New Corporate Structure to Achieve U.S. Domiciliation
Indivior PLC plans to change its corporate domicile from the U.K. to the U.S. by establishing a new parent company, Indivior Pharmaceuticals, Inc. This move follows its recent U.S. listing on Nasdaq and aims to leverage the benefits of being based in the U.S. The transition will require shareholder approval and is expected to enhance shareholder value.
Read more →INDV▲ +16.1%on this news
Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance
Indivior PLC reported strong financial results for the second quarter of 2025, leading to an increase in its financial guidance for the year. The growth was driven by net revenue from SUBLOCADE and stable pricing for SUBOXONE Film. CEO Joe Ciaffoni emphasized the company's commitment to operational improvements and future revenue growth as they implement their Indivior Action Agenda.
Read more →INDVIndivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained
Indivior PLC has announced the cancellation of its secondary listing on the London Stock Exchange, effective July 25, 2025. The company will continue to maintain its primary listing on the Nasdaq Stock Market. This decision follows an earlier announcement made on June 2, 2025, and is part of Indivior's strategy to focus on its primary market.
Read more →INDVIndivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder Indivior PLC (Nasdaq/LSE: INDV) today announced results from a new retrospective real-world study published in Drug and Alcohol Dependence Reports,...
Indivior PLC announced positive findings from a real-world study published in Drug and Alcohol Dependence Reports, which focuses on opioid use disorder (OUD) patients. The study indicated that patients treated with BUP-XR, an extended-release formulation of buprenorphine, experienced 57% fewer emergency department visits compared to those not receiving medication for opioid use disorder. Furthermore, this cohort demonstrated lower hospitalization rates and inpatient costs. However, the study's limitations include a sample that may not represent all OUD patients and a limited observation period of six months.
Read more →INDVIndivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st Indivior PLC (Nasdaq / LSE: INDV) today announced that it will report second quarter 2025 financial results on Thursday, July 31, 2025 at 7:00 a.m. U....
Indivior PLC has announced it will report its financial results for the second quarter of 2025 on July 31, 2025. Following the report, CEO Joe Ciaffoni and the leadership team will conduct a live webcast presentation to discuss the results. The event will be available for access through the company's website, with replay options following the presentation. Indivior focuses on tailored treatments for opioid use disorder and aims to enhance patient care worldwide.
Read more →INDVIndivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July ...
Indivior PLC has appointed Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Procter, with 25 years in the biopharmaceutical field, will oversee Corporate Communications, Government Affairs, Policy, and Advocacy. Her extensive experience includes previous leadership roles at Sage Therapeutics and Alexion Pharmaceuticals. Indivior aims to expand access to treatments for opioid use disorder, and Procter's expertise is anticipated to benefit the company's mission significantly.
Read more →INDV▲ +5.7%on this news
Indivior Announces Inclusion in the U.S. Russell 2000 and 3000 Indexes Richmond, VA
Indivior PLC is set to be added to the U.S. small-cap Russell 2000 Index as part of the annual reconstitution of the Russell indexes. This inclusion is expected to enhance Indivior's presence in capital markets, coinciding with the company's growth in the U.S. market, where it generated 85% of its net revenue in 2024. The move aligns with Indivior's commitment to expanding its influence and value for stakeholders, particularly in the opioid use disorder treatment sector.
Read more →INDV▲ +5.7%on this news
Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes Indivior PLC (Nasdaq / LSE: INDV) will be added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens today as ...
Indivior PLC has been added to the U.S. small-cap Russell 2000 Index as part of the 2025 Russell indexes reconstitution. This inclusion reflects the company's growing presence in the U.S. market, where it generated 85% of its net revenue in 2024, primarily from its opioid use disorder treatment, SUBLOCADE. The Russell indexes are significant benchmarks for investment strategies, managing approximately $10.6 trillion in assets.
Read more →INDVIndivior Appoints Tony Kingsley to the Board of Directors Richmond, VA
Indivior PLC has appointed Tony Kingsley as an Independent Non-Executive Director, effective July 1, 2025. Kingsley brings extensive biopharmaceutical experience, having held leadership roles in various companies including Stablix, Scholar Rock, and TARIS Bio. His track record is expected to aid Indivior in realizing the potential of its treatments for opioid use disorder. The appointment aligns with Indivior's mission to enhance its position in the field and deliver value to stakeholders.
Read more →INDVIndivior Appoints Tony Kingsley to the Board of Directors Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive...
Indivior PLC has appointed Tony Kingsley as an Independent Non-Executive Director, effective July 1, 2025. Kingsley, an experienced biopharmaceutical executive, is expected to contribute significantly to Indivior's mission of addressing opioid use disorder. His previous leadership roles in various biotech companies highlight his capability to drive growth and innovation.
Read more →INDVIndivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users Indivior PLC (Nasdaq: INDV) presented new findings this week at the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting. A post...
Indivior PLC (Nasdaq: INDV) presented new findings at the CPDD Annual Scientific Meeting, indicating that higher doses of SUBLOCADE may improve treatment outcomes for patients with high fentanyl use. While the 300 mg dose did not provide a statistically significant advantage in overall weekly abstinence, it did show meaningful improvements for those with severe opioid use issues. Additionally, research highlighted barriers faced by American Indian/Alaska Native populations in accessing treatments for opioid use disorder, emphasizing the need for culturally appropriate care solutions.
Read more →INDVInvestor Presentation June 2025 For Investor Relations Purposes Only I N V E S T O R P R E S E N T A T I O N | J U N E 2 0 2 5 Important Cautionary Statement Regarding Forward-looking Statements This presentation contain
Indivior (INDV) presented its investor outlook for June 2025, highlighting strong projected revenues of $1,188 million for FY2024 and ongoing leadership in opioid dependence treatments with products like SUBLOCADE. The presentation also addressed potential headwinds, including revenue declines from generic competition and funding issues within the Criminal Justice System. Despite these challenges, Indivior is focused on expanding its product pipeline and enhancing operational efficiency to achieve growth.
Read more →INDVIndivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained Indivior PLC (Nasdaq/LSE: INDV) today announced its intention to cancel: (i) the secondary listing of the Company's Ordinary Shares ( Ordinary...
Indivior PLC has announced its intention to cancel its secondary listing of Ordinary Shares on the London Stock Exchange, maintaining its primary listing on Nasdaq. This decision follows a review of the company's listing structure, aiming to enhance liquidity and reduce administrative costs. The London Delisting is scheduled to take effect on July 25, 2025, easing trading complexities for shareholders. Indivior anticipates this move will better align with its business profile and global operations.
Read more →INDVTHIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596 2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE U.K. BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL ACT 2018)
Indivior PLC announced its intention to cancel its secondary listing on the London Stock Exchange while maintaining its primary listing on Nasdaq. The decision is based on the evaluation of trading volumes, shareholder location, and operational costs. The Board believes that this move will better reflect the company's U.S.-focused revenue profile and simplify its listing structure. The London Delisting is expected to be effective from July 25, 2025, and aims to better align the company with its major market.
Read more →INDV▲ +5%on this news
Indivior Announces Patrick Barry as Chief Commercial Officer Indivior PLC (Nasdaq/LSE: INDV) today announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. In this role, Barry...
Indivior PLC has announced the appointment of Patrick Barry as Chief Commercial Officer, effective June 2. With over 30 years of experience in the pharmaceutical industry, Barry will direct Indivior's commercial growth strategy and operations. He previously led commercial activities at Endo Pharmaceuticals and has a history of success in various leadership roles. Barry's expertise is expected to aid Indivior in enhancing its position in the treatment of opioid use disorder.
Read more →INDVIndivior to Participate in Upcoming Investor Events Indivior PLC (NASDAQ/LSE: INDV) today announced that it will participate in the following investor events: Jefferies Global Healthcare Conference –...
Indivior PLC has announced its participation in several investor events scheduled for June 2025. CEO Joe Ciaffoni and CFO Ryan Preblick will host meetings and discussions, enhancing investor engagement. The company emphasizes its commitment to addressing substance use disorders through innovative treatments and a strong product pipeline.
Read more →INDVIndivior PLC (the Company') Result of Annual General Meeting ( AGM')
Indivior PLC has announced the results of its Annual General Meeting (AGM), where all proposed resolutions were passed by shareholders. The company reported that the majority of votes reached overwhelming support, particularly for the Directors' Remuneration Report and the election of new board members. Detailed results of the votes were published, demonstrating a strong alignment between shareholders and the company's management decisions. This indicates a solid foundation for Indivior moving forward.
Read more →INDVNew Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy Indivior PLC (Nasdaq/LSE: INDV) today announced the publication of a study Monthly Buprenorphine Depot Injection (SUBLOCADE) for Opioid Use Disorder ...
Indivior PLC announced the publication of a study evaluating the use of SUBLOCADE for opioid use disorder treatment during and after pregnancy. The research, published in the American Journal on Addictions, found that the drug showed no increased risks of birth defects or maternal complications, adhering to established safety profiles of buprenorphine. Clinical data from four case studies and over 300 reports of pregnancy exposures were analyzed, indicating positive outcomes for mother and child. This study aims to improve understanding and treatment options for pregnant patients facing opioid use disorder.
Read more →INDV▲ +13.9%on this news· ran to +24% by day 3
Indivior Announces Q1 2025 Financial Results Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending March 31, 2025. The earnings release, investor...
Indivior PLC announced its financial results for Q1 2025, ending March 31, 2025. The company focuses on developing treatments for opioid use disorder and aims to provide evidence-based treatment access globally. A webcast detailing the financial results will be hosted by CEO Mark Crossley. Indivior's commitment to OUD treatment is reflected in their expanding portfolio and pipeline of products.
Read more →INDV▲ +5.8%on this news
Indivior Announces Further Changes to Board of Directors Indivior PLC (NASDAQ / LSE: INDV) ( Indivior or the Company ) today announced that, further to the announcement on December 17, 2024 of certain...
Indivior PLC has announced additional changes to its Board of Directors following prior appointments and arrangements with Oaktree Capital Management. Key figures, including Dr. David Wheadon, expressed gratitude to outgoing directors for their contributions towards treating opioid use disorder. The company has also revised its Relationship Agreement with Oaktree to reflect these changes. Indivior remains focused on advancing its mission to provide effective treatments for substance use disorders on a global scale.
Read more →INDVIndivior Announces Joseph Ciaffoni Appointed Chief Executive Officer Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive...
Indivior PLC has appointed Joe Ciaffoni as the new Chief Executive Officer, effective upon shareholder approval of a new remuneration policy at the AGM in May 2025. With over 30 years of experience in the sector, Ciaffoni previously served as President and CEO of Collegium Pharmaceutical. He is expected to lead Indivior towards its next growth phase, while Mark Crossley will step down after a successful tenure but remain during the transition. The change in leadership aligns with the company's ongoing mission to improve treatment access for substance use disorders.
Read more →INDVIndivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection Indivior PLC (Nasdaq/LSE: INDV), a global leader in addiction treatment, today announced that the U.S. Food and Drug Administration (FDA) has...
Indivior PLC has received FDA approval for significant label changes to SUBLOCADE, enhancing its use in treating moderate to severe opioid use disorder. The updates include a rapid initiation protocol that can reduce the time to treatment from one week to just one hour. Additionally, alternative injection sites will provide greater flexibility for patients and healthcare providers. These changes are intended to improve patient adherence and treatment outcomes without altering the drug's existing safety profile.
Read more →INDV▼ -17.6%on this newsshared move
Indivior Announces FY and Q4 2024 Financial Results Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024. The earnings release, investor...
Indivior PLC has announced its financial results for the fiscal year and the fourth quarter ending December 31, 2024. The earnings release includes a live webcast presentation hosted by CEO Mark Crossley. Indivior continues its dedication to addressing substance use disorders with a focus on evidence-based treatment and expanding its product pipeline. The company operates globally, with its products available in over 30 countries.
Read more →INDV▼ -17.6%on this newsshared move
Document
Indivior PLC announced its FY 2024 financial results and guidance for FY 2025, reporting a 9% increase in net revenue to $1,188 million. Despite robust growth in SUBLOCADE, with a 20% year-on-year rise in revenue, the company anticipates a 17% revenue decline in FY 2025, primarily due to the erosion of SUBOXONE Film revenue from increased generic competition. The company is streamlining its operations to save over $100 million annually, with efforts focused on supporting long-term growth in its opioid use disorder treatment pipeline. Indivior remains committed to its strategic objectives despite these challenges.
Read more →INDVIndivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes Indivior PLC (Nasdaq/LSE: INDV) provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and...
Indivior PLC announced that the FDA has delayed the final review of the label changes for SUBLOCADE, originally scheduled for February 7, 2025. While the FDA accepted the proposed label with no outstanding items to address, the review process will take longer than expected. Indivior plans to provide further updates regarding the approval status of the changes as necessary. This delay could have implications for the company and its stakeholders.
Read more →INDVINDIVIOR
Indivior PLC announced the completion of a share repurchase, buying back 250,835 ordinary shares of its $0.50 stock between December 2 and December 6, 2024. This purchase was part of a $100 million Share Repurchase Program. Following the cancellation of the shares, Indivior will have a total of 125,481,525 ordinary shares outstanding with voting rights. The transactions were executed through Morgan Stanley & Co. International Plc and adhere to market regulations.
Read more →INDVINDIVIOR PLC (THE 'COMPANY') TOTAL VOTING RIGHTS AND CAPITAL In accordance with the FCA's Disclosure Guidance and Transparency Rule 5.6.1, the Company hereby notifies the market that as at
Indivior PLC has announced its total voting rights and capital as of December 1, 2024. The company reported an issued share capital of 125,732,360 Ordinary Shares each valued at US$0.50. There are no shares held in Treasury, making the total number of voting rights equal to the issued shares. This information is provided in compliance with the FCA's Disclosure Guidance and Transparency Rules.
Read more →INDVRapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024 Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among...
Indivior PLC presented promising data at the 2024 CSAM conference regarding the effectiveness of rapid initiation (RI) with SUBLOCADE for treating opioid use disorder (OUD). The randomized study demonstrated that RI improves retention rates significantly compared to standard initiation, especially in fentanyl-positive patients. Additionally, the data highlighted that RI may facilitate quicker patient stabilization without increasing withdrawal risks. Following this, the FDA has granted Priority Review designation for a labeling supplement to include RI methods, signaling potential for broader application upon approval.
Read more →INDV▼ -5.3%on this news
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior Richmond, VA
Indivior PLC has acknowledged the publication of a letter from Oaktree Capital Management to its Board of Directors. The Board has been actively engaging with Oaktree on various proposals aimed at enhancing value for shareholders. Indivior remains committed to its mission of providing innovative treatments for substance use disorders and continues to expand its global portfolio. The company looks forward to ongoing discussions with Oaktree and its other shareholders.
Read more →INDV▲ +16.3%on this newsshared move
Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior Indivior PLC (NASDAQ / LSE: INDV) the Board of Directors (the "Board") of Indivior plc ("Indivior" or the "Company") notes the publication today of a ...
Indivior PLC acknowledges a letter from Oaktree Capital Management and emphasizes its commitment to shareholder engagement. The Board is open to proposals aimed at enhancing value creation while continuing to execute its strategic plans. Indivior aims to transform substance use disorders into recognized chronic diseases through its innovative treatments.
Read more →INDVIndivior Completes Refinance of Secured Term Loan; Enhances Liquidity and Financial Flexibility Richmond, VA
Indivior PLC has successfully refinanced its secured term loan by entering an agreement to issue $400 million in senior secured notes. The deal includes $350 million in term notes and a $50 million revolving credit facility. Proceeds from the refinancing will fully repay the existing term loan and fund working capital needs, enhancing the company's liquidity by over $250 million. This move is expected to bolster Indivior's financial flexibility for future operational and strategic initiatives.
Read more →INDVNote Purchase Agreement RBP Global Holdings Limited (the Issuer ), which is an indirect, wholly-owned subsidiary of Indivior PLC, entered into a note purchase agreement dated as of
Indivior PLC's subsidiary, RBP Global Holdings Limited, has entered into a note purchase agreement for $350 million in term loan notes. The agreement also permits the issuance of an additional $50 million in variable notes. The financial structure includes various covenants and the ability to secure further financing under certain conditions. This arrangement reflects Indivior's efforts to enhance its capital structure for future growth.
Read more →INDVIndivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month Indivior PLC (Nasdaq/LSE: INDV), in recognizing Substance Abuse Prevention Month, provides an update on key findings from the last year that...
Indivior PLC has released an update in honor of Substance Abuse Prevention Month, showcasing findings that emphasize the efficacy of SUBLOCADE in treating opioid use disorder (OUD). The data points to improved patient outcomes, such as increased abstinence and retention rates. However, the company also highlighted serious risks associated with the drug, mandating careful administration and ongoing patient monitoring. Indivior's commitment to enhancing treatment access remains pivotal as they address the challenges faced by individuals with OUD.
Read more →INDVIndivior Announces Q3 2024 Financial Results Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending September 30, 2024. The earnings release, investor...
Indivior PLC announced its financial results for the third quarter of 2024, highlighting its ongoing efforts to tackle substance use disorders and related mental health conditions. The company's CEO, Mark Crossley, will host a live webcast to discuss the earnings in detail. Indivior aims to expand its portfolio of treatments for opioid use disorders and provide access to care on a global scale. The company operates from Richmond, VA and serves markets in over 30 countries.
Read more →INDV▼ -15.5%on this news
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of $1.5 Billion Indivior PLC (Nasdaq/LSE: INDV) today announced preliminary Q3 2024 financial results and provided updated FY 2024 guidance. Group now sees lower...
Indivior PLC announced preliminary financial results for Q3 2024, revealing a reduction in FY 2024 guidance due to competitive pressures impacting SUBLOCADE's revenue expectations. The company noted faster adoption of a competitor's product, which has contributed to lower net revenue than previously anticipated. Despite these challenges, Indivior maintains confidence in SUBLOCADE's profile for treating opioid use disorder and anticipates label updates that may enhance its market position. Preliminary expectations indicate an increase in net revenue compared to Q3 2023.
Read more →INDVIndivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review Indivior PLC (Nasdaq/LSE: INDV) today announced the Prior Approval Supplement (PAS) for SUBLOCADE® (buprenorphine extended-release) injection...
Indivior PLC announced that the FDA has granted Priority Review for its Prior Approval Supplement (PAS) concerning SUBLOCADE, its injectable treatment for opioid use disorder. This designation accelerates the review process, with a decision expected by February 7, 2025. The proposed updates include enhancements to the drug's label aimed at expanding its use and improving patient experience, particularly for those with long-term opioid use. The approval could represent a significant advance in treatment options for managing opioid use disorder.
Read more →INDVIndivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma's announcement of the results from its clinical Phase 2B trial...
Indivior PLC has provided an update regarding the clinical Phase 2B trial results of AEF0117, developed by Aelis Farma, for treating Cannabis Use Disorder. The study aimed to evaluate the efficacy and safety in treatment-seeking participants but failed to meet its primary and secondary endpoints, disappointing stakeholders. As a result, Indivior does not plan to exercise its licensing option for AEF0117 until more favorable clinical data is available. The trial highlighted the need for further understanding of subpopulations, particularly those with severe cases of Cannabis Use Disorder.
Read more →INDVIndivior Announces BARDA's First Order of OPVEE® to Combat Opioids and Aid in National Preparedness Indivior PLC (LSE/Nasdaq: INDV) today announced the first order of OPVEE® (nalmefene) nasal spray from the Biomedical Advanced Research and...
Indivior PLC announced a significant order of its OPVEE (nalmefene) nasal spray from the Biomedical Advanced Research and Development Authority (BARDA) to support U.S. national preparedness efforts against synthetic opioid overdoses. With over 76,922 fatal overdoses reported in the past year, OPVEE serves as a crucial emergency treatment option for first responders. Funded by $8.7 million in federal Project BioShield funds, BARDA's procurement marks a vital step in addressing the escalating opioid crisis in the U.S. Indivior's partnership with BARDA allows for additional orders under a long-term agreement to bolster local supplies during emergencies.
Read more →INDV▲ +20.3%on this news
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (
Indivior PLC has announced the initiation of a new $100 million share repurchase program, which will be executed on an accelerated basis over the next six months. This follows the decision to expedite the completion of its current repurchase program, originally set for late August 2024, now expected to conclude by the end of July 2024. The new program will be carried out by Morgan Stanley, which will independently make purchasing decisions under a non-discretionary agreement. These initiatives highlight Indivior's ongoing strategy to manage its issued share capital effectively.
Read more →INDV▲ +20.3%on this news
Indivior Announces a New $100 Million Share Repurchase Program; New Program will be Executed Over an Accelerated Time Frame Indivior PLC (Nasdaq/LSE: INDV) ( Indivior or the Company ), a leading addiction treatment company, today announced that its Board of Directors has ...
Indivior PLC has approved a new share repurchase program worth $100 million, set to be executed over the next six months. This decision reflects the company's commitment to return capital to shareholders while reducing its issued share capital. Additionally, the current $100 million repurchase program, originally slated for completion by August 2024, is being expedited to conclude by the end of July 2024. The company plans to work with Morgan Stanley for the execution of this program under a non-discretionary agreement.
Read more →INDV▲ +20.3%on this news
Indivior Announces Q2 2024 Financial Results Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending June 30, 2024. The earnings release, investor...
Indivior PLC has announced its financial results for the second quarter of 2024. The company aims to improve treatment access for substance use disorders and is developing a range of medicines in this field. The CEO, Mark Crossley, will host a live webcast to discuss the results and provide further insights. Indivior's commitment to addressing chronic conditions and expanding its treatment portfolio highlights its ongoing efforts to combat substance use disorders.
Read more →INDV▼ -33.6%on this news
Indivior Provides Business Update; Conference Call at 8:00 AM U.S. EDT Indivior PLC (Nasdaq/LSE: INDV) today announces a business update encompassing the Group's outlook for Q2 and FY 2024 financial performance, its...
Indivior PLC has announced a business update detailing its outlook for Q2 and FY 2024, including a revision of revenue guidance downward due to unforeseen impacts affecting its drug SUBLOCADE. Although the company expects SUBLOCADE's net revenue to grow by 25%, it faces challenges from ongoing Medicaid disenrollments and stocking issues. Additionally, Indivior reached a settlement in its antitrust litigation, agreeing to pay $85 million which will be excluded from adjusted earnings. The company reaffirms its long-term revenue targets and continues to navigate a complex market landscape.
Read more →INDVTR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BN4HT335 Issuer Name INDIVIOR PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights; Other Com
Indivior PLC has issued a notification concerning major holdings regarding the acquisition and disposal of voting rights. The notification indicates that the overall percentage of voting rights held by a certain shareholder has crossed the threshold of 6%. Specific details about the voting rights and financial instruments associated with this change have been provided. The data showcases a slight increase in voting rights compared to previous notifications.
Read more →INDVTR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BN4HT335 Issuer Name INDIVIOR PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Details
Indivior PLC has filed a notification of major holdings, indicating changes in voting rights regarding its shares. The notification outlines that the shareholder's voting rights have fallen below 5%. Details included the percentages of direct and indirect voting rights held, as well as information on financial instruments. Additionally, BlackRock, Inc. and its affiliates are identified as significant shareholders involved in this notification.
Read more →INDVIndivior Announces the Publication of New Data on the Comparative Effectiveness of Intranasal (IN) Nalmefene (OPVEE 2.7mg) and IN Naloxone (4 mg) in a Translational Model Assessing the Impact of a Synthetic Opioid Overdose on Respiratory Depression and Cardiac Arrest Large reductions in the incidence of simulated cardiac arrest caused by potentially lethal doses of fentanyl or carfentanil were observed following a ...
Indivior PLC announced the publication of a new modeling study demonstrating that its OPVEE nasal spray (nalmefene) is more effective than naloxone in reducing cardiac arrest incidents caused by synthetic opioid overdoses. The study, published in Frontiers in Psychiatry, utilized a validated translational model to simulate the impact of fentanyl and carfentanil overdoses. The results showed a significant reduction in cardiac arrest incidence with OPVEE compared to naloxone. This research underscores the challenges of effectively reversing synthetic opioid overdoses and aims to aid first responders in managing these critical situations.
Read more →INDVIndivior Announces Dosing of First Subject with INDV-2000 in a Phase 2 Study Assessing the Safety and Efficacy of INDV-2000 in Individuals with Opioid Use Disorder Double-blind, placebo-controlled study aims to measure safety and efficacy of INDV-2000 over 3 months in participants with moderate to severe Opioid...
Indivior PLC has initiated a Phase 2 clinical study for INDV-2000, a non-opioid treatment for Opioid Use Disorder (OUD), with the first subject dosed. This proof-of-concept study aims to assess the safety and efficacy of INDV-2000 over three months in treatment-seeking individuals. The study has received support from an NIH-HEAL grant and intends to evaluate the dose-response relationship of INDV-2000 among participants who have completed medically supervised opioid withdrawal. Indivior's commitment to expanding treatment options for OUD is highlighted by this milestone amidst the ongoing opioid crisis.
Read more →INDVIndivior to Host Analyst Teach-in Event in New York City; Reconfirms Full Year 2024 Guidance Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, announced that in anticipation of the expected primary listing of the...
Indivior PLC has announced an analyst teach-in event scheduled for today in New York City, where its senior leadership will discuss the company's growth strategy and confirm its financial guidance for FY 2024. The guidance anticipates a net revenue of $1.24 billion to $1.33 billion, marking an increase compared to FY 2023. Key product forecasts include significant revenue expectations for SUBLOCADE and PERSERIS, reflecting the company's strong position in the addiction treatment market. Indivior also highlights their ongoing commitment to addressing substance use disorders on a global scale.
Read more →INDVIndivior To Participate in Upcoming Investor Events Slough, UK, and Richmond, VA
Indivior PLC has announced its participation in upcoming investor events, including the Craig-Hallum Institutional Investor Conference in Minneapolis and the Jefferies Global Healthcare Conference in New York City. The CEO, Mark Crossley, will host a presentation at the Jefferies conference, which will be publicly available. Indivior focuses on developing medicines for substance use disorders and aims to provide access to evidence-based treatment worldwide. The company is headquartered in Richmond, VA and employs over 1,100 people globally.
Read more →INDVIndivior PLC (the 'Company') Result of Annual General Meeting ('AGM')
Indivior PLC announced the results of its Annual General Meeting (AGM) where all resolutions were passed by poll. Significant support was noted for most proposals, indicating shareholder confidence. However, resolutions related to board member elections saw substantial opposition, particularly for three members who do not hold shares in the company. The Board emphasized the importance of addressing shareholder feedback and plans to engage with those who voted against the resolutions.
Read more →INDV▼ -8.3%on this news
Indivior Announces Q1 2024 Financial Results Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending March 31, 2024. The earnings release, investor...
Indivior PLC has announced its financial results for the first quarter ending March 31, 2024. The company remains committed to developing medications for substance use disorders and chronic conditions. In addition, a live webcast presentation will provide further details regarding their performance. Indivior emphasizes its dedication to transforming substance use disorders into recognized chronic diseases with evidence-based treatments.
Read more →INDVIndivior to Announce Q1 2024 Results and Host Webcast on April 25 th Slough, UK, and Richmond, VA
Indivior PLC has announced that it will release its Q1 2024 financial results on April 25, 2024, at 7:00 a.m. London time. Following the results announcement, a live webcast will be hosted by Chief Executive Officer Mark Crossley and other leadership team members at 1:00 p.m. London time to discuss the outcomes. This event underscores Indivior's commitment to developing drugs for substance use disorders and related conditions.
Read more →INDVINDIVIOR PLC (THE 'COMPANY') NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ('PDMR') AND PERSONS CLOSELY ASSOCIATED WITH THEM The Company announces that on
Indivior PLC announced that on March 15, 2024, Ryan Preblick, the Chief Financial Officer and a person discharging managerial responsibilities (PDMR), had an award of 7,140 Ordinary Shares vest under the company's Deferred Bonus Plan 2018. The vesting follows a two-year deferral period and was not subject to performance conditions. Following this transaction, Preblick holds an interest in a total of 68,386 shares. This disclosure is part of the company's compliance with the UK's Market Abuse Regulation.
Read more →INDVSECURITIES AND EXCHANGE COMMISSION
Indivior PLC has filed a report with the SEC, indicating compliance with annual reporting requirements under the Securities Exchange Act of 1934. The document includes details of its annual report and accounts for the year ended December 31, 2023. The filing was officially signed by Kathryn Hudson, the Company Secretary, on March 13, 2024.
Read more →INDVTR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BN4HT335 Issuer Name INDIVIOR PLC UK or Non-UK Issuer Non-UK 2. Reason for Notification An acquisition or disposal of voting rights 3. Det
Indivior PLC has reported a notification of major holdings under the TR-1 standard form. The report details an acquisition of voting rights bringing the total to 6.03% held by a shareholder. This marks a slight increase from a previous notification where the holdings were at 5.9992%. The specific shareholder’s details and date of the crossing threshold are also included in the report.
Read more →INDVINDIVIOR PLC (THE 'COMPANY') NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM The Company announces that, subsequent to the de
Indivior PLC announced the sale of 23,470 shares by Christian Heidbreder, the Chief Scientific Officer, following the exercise of a share option. The option, granted in 2014, allowed Heidbreder to purchase shares at a price of US$ 7.024 each. The subsequent sale was executed over three days, fetching an average price of US$ 20.84 per share. Following these transactions, Heidbreder maintains a beneficial interest in 92,922 shares of the company.
Read more →INDVIndivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone Indivior PLC (LSE/Nasdaq: INDV) today announced results from a pharmacodynamic study demonstrating that OPVEE® rapidly reverses opioid-induced...
Indivior PLC announced the successful results of a pharmacodynamic study for OPVEE (nalmefene) that showed it rapidly reverses opioid-induced respiratory depression. This head-to-head study against intranasal naloxone found OPVEE achieved a significant reversal within 5 minutes, compared to 20 minutes for naloxone. The findings were published in the Journal of Clinical Pharmacology and underscore OPVEE's potential as a critical tool in reversing opioid overdoses caused by synthetic opioids. Despite a high occurrence of adverse events, the results highlight OPVEE's advantages in emergency situations.
Read more →INDVCourt Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final ...
Indivior PLC has received final court approval for a $385 million settlement with the Direct Purchaser class, concluding an antitrust multidistrict litigation. The United States District Court for the Eastern District of Pennsylvania has officially granted judgment, dismissing the claims from the Direct Purchaser class. This resolution allows Indivior to move forward without the burden of ongoing legal disputes, enabling the company to refocus on its core objectives in addiction treatment.
Read more →INDV▲ +21.7%on this news
Indivior Announces Q4 / FY 2023 Financial Results Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending December 31, 2023. The earnings release, investor...
Indivior PLC has announced its financial results for the fiscal year ending December 31, 2023. The company is dedicated to developing medicines for substance use disorders and serious mental illnesses. As a global pharmaceutical leader, Indivior aims to transform substance use disorders into recognized chronic diseases with adequate treatment options. The results are accompanied by a live webcast presentation featuring insights from CEO Mark Crossley.
Read more →INDVINDIVIOR PLC (THE 'COMPANY') - DIRECTOR/PDMR SHAREHOLDINGS - CORRECTION The following amendment has been made to the 'Director/PDMR Shareholding' announcement released on
Indivior PLC announced a correction to its previous 'Director/PDMR Shareholding' statement. An error in the number of shares acquired by Non-Executive Director Mark Stejbach was corrected from 1,400 to 1,300 shares. Following this purchase, Stejbach now holds 9,584 shares in total. The transaction took place on March 6, 2023, at an average price of £15.0229 per share, and details regarding other shareholdings remained unchanged.
Read more →INDV▼ -5.5%on this news· ran to -17% by day 1
Indivior Announces Q3 2023 Financial Results Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending September 30, 2023. The earnings release, investor...
Indivior PLC has released its financial results for the third quarter of 2023, reflecting ongoing progress in its operations. The company is focused on addressing substance use disorders and aims to provide global access to evidence-based treatments. Indivior's commitment to innovation and expansion in therapeutic options is highlighted, as it continues to work on a pipeline of products targeting various conditions. A live webcast presentation of the financial results is scheduled for later today.
Read more →INDVIndivior Enters an Exclusive Licensing Agreement with Alar Pharmaceuticals Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, today announced that it has gained exclusive global rights to develop,...
Indivior PLC has entered into an exclusive licensing agreement with Alar Pharmaceuticals to develop and commercialize long-acting injectable formulations, including ALA-1000, which is designed to treat opioid use disorder (OUD). This agreement grants Indivior global rights to ALA-1000, potentially the first three-month long-acting injectable buprenorphine treatment. The arrangement comes with an initial $5 million option payment and a subsequent $10 million payment, alongside milestone payments to Alar based on developmental successes. The collaboration aims to enhance treatment options for patients, particularly those requiring less frequent dosing.
Read more →INDVIndivior Publishes Real World Data Showing SUBLOCADE® May Reduce Non-Fatal Overdoses Among Individuals with Opioid Use Disorder in Canada Indivior PLC (LSE/Nasdaq: INDV) today announced the publication of a retrospective chart review analysis of individuals treated for opioid use...
Indivior PLC published a study showing that SUBLOCADE, an extended-release buprenorphine injection, may significantly reduce non-fatal overdoses among individuals with opioid use disorder in Canada. The retrospective chart review indicated a lower incidence of self-reported overdoses compared to sublingual buprenorphine/naloxone and methadone. While the findings suggest positive clinical benefits, the study underscores the need for prospective research to further validate these results due to its observational design.
Read more →INDV▲ +6%on this news
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims Indivior PLC (LSE/Nasdaq: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the Company ), has reached an...
Indivior PLC has reached an agreement to resolve claims from the end payor class in the multi-district litigation concerning Suboxone. The proposal includes a $30 million settlement, pending initial approval from the U.S. District Court and participation from appropriate end payors. This resolution allows Indivior to focus on its core mission despite ongoing preparations for trial regarding other claims set for October 2023.
Read more →INDV▲ +6%on this news
Indivior Reaches Agreement with End Payor Class to Resolve Their Antitrust Multi-District Litigation Claims Richmond, VA
Indivior PLC announced that it has reached an agreement to settle claims brought by the end payor class in the Suboxone antitrust litigation. This settlement involves a payment of $30 million, which is part of a larger provision of $188 million. The agreement is pending approval from the United States District Court and requires participation from an appropriate number of end payors. Meanwhile, the company is also preparing for an upcoming trial related to other claims in the case.
Read more →INDVINDIVIOR PLC (THE COMPANY ) TOTAL VOTING RIGHTS AND CAPITAL In accordance with the FCA s Disclosure Guidance and Transparency Rule 5.6.1, the Company hereby notifies the market that as at
Indivior PLC has announced its total voting rights and capital as of August 1, 2023. The company reports an issued share capital of 137,939,173 Ordinary Shares, each valued at US$0.50. No shares are held in Treasury, which means the total number of voting rights is equal to the issued shares. This information is essential for shareholders to determine their obligations under the FCA's Disclosure Guidance and Transparency Rules.
Read more →INDVDocument The information contained within this announcement is deemed by the Company to constitute inside information as stipulated by the Market Abuse Regulation (EU) No.596 2014, as it forms part of UK law by virtue of
Indivior PLC has reported strong financial performance for the first half of 2023, with net revenues increasing by 24% year-over-year. The launch of OPVEE, an opioid overdose reversal agent, is anticipated in Q4 2023, which adds to the company's growth prospects. Despite the increase in revenues, the company experienced declines in net income and operating profit for the second quarter. The updated guidance reflects improved revenue expectations for SUBLOCADE, while the impact of competing products on SUBOXONE's market share is being closely monitored.
Read more →INDVIndivior Announces Q2/H1 2023 Financial Results Indivior PLC (LSE/Nasdaq: INDV) today announced its financial results for the period ending June 30, 2023. The earnings release, investor...
Indivior PLC announced its financial results for the second quarter and first half of 2023, showcasing a strong performance. The results were made public through an investor presentation and webcast, hosted by CEO Mark Crossley. The company remains dedicated to addressing substance use disorders by expanding its portfolio and offering global access to evidence-based treatment.
Read more →INDVTR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BN4HT335 Issuer Name INDIVIOR PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of voting rights; An acquis
Indivior PLC has announced a notification regarding major holdings as specified by the TR-1 form. Morgan Stanley has acquired a percentage of voting rights, resulting in a total holding of 5.24%. This includes direct and indirect voting rights detailed in the report. No specific implications or future actions have been indicated at this time.
Read more →INDVIndivior PLC (the Company ) Indivior PLC confirms that Jerome Lande, Non-Executive Director, has advised that he will be appointed as a Non-Executive Director of R&Q Insurance Holdings Ltd (AIM:RQIH), subject to the sati
Indivior PLC has announced that Jerome Lande, a Non-Executive Director, will take up a similar position at R&Q Insurance Holdings Ltd, pending successful due diligence checks. This move aligns with Listing Rule 9.6.14 and reflects changes in leadership within the company. The announcement emphasizes standard protocols followed during such transitions.
Read more →INDV▲ +6%on this newsshared move
TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BN4HT335 Issuer Name INDIVIOR PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal of financial instruments 3.
Indivior PLC has disclosed a significant notification of major holdings as per TR-1 standards. The report mentions Morgan Stanley's recent acquisition which brings the total voting rights held to approximately 6.95%. The notification includes details about both direct and indirect voting rights, as well as financial instruments that may influence the shareholder structure. Such notifications are crucial for maintaining transparency among stakeholders regarding significant shareholder changes.
Read more →INDVIndivior to Announce Q2 and H1 2023 Results on July 27 th Slough, UK, and Richmond, VA
Indivior PLC has announced the release of its Q2 and H1 2023 financial results, scheduled for July 27th at 7:00 a.m. London time. The results will be accessible through the London Stock Exchange's Regulatory News Service and the company's website. A live webcast presentation led by CEO Mark Crossley will take place on the same day at 1:00 p.m. London time. Indivior is focused on developing treatments for substance use disorders and aims to make these chronic conditions more recognized and treated globally.
Read more →INDVTR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying
Indivior PLC has received a notification from Scopia Capital Management LP and Scopia Management, Inc. regarding their major holdings in the company. As of June 19, 2023, they hold a 6.96% stake, down from a previous holding of 8.98%. This notification is part of standard regulatory requirements for significant shareholdings. The notification was officially completed on June 21, 2023, and involves compliance with the UK's FCA regulations.
Read more →INDVIndivior Announces Four Abstracts Accepted for Presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence Indivior PLC (LSE/Nasdaq: INDV) today announced the acceptance of four abstracts for presentation at the 85th Annual Scientific Meeting of the...
Indivior PLC announced the acceptance of four research abstracts for presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence. These abstracts focus on patients with cannabis use disorder and opioid use disorder treated with extended-release buprenorphine. The findings aim to provide insights into the daily challenges and motivations of recovery among these patients. The meeting will take place from June 17-21, 2023, in Denver, Colorado.
Read more →INDVIndivior to Commence Trading on Nasdaq Company to Ring Opening Bell June 14 to Bring Awareness to Addiction Treatment; Company Will Maintain Premium Listing on London Stock Exchange Richmond, VA
Indivior PLC has announced the commencement of trading on the Nasdaq Global Select Market, effective from June 12, 2023. The company retains its premium listing on the London Stock Exchange and plans to ring the Nasdaq opening bell on June 14 to raise awareness about addiction treatment. CEO Mark Crossley emphasized the goal of increasing exposure to both Indivior and the urgent needs in the U.S. concerning opioid use disorder. Indivior is also launching a patient-focused campaign alongside the Nasdaq listing to humanize addiction and promote recovery.
Read more →INDVIndivior to Commence Trading on Nasdaq Indivior PLC (LSE: INDV), a global pharmaceutical company working to help change patients' lives by developing medicines to treat substance use...
Indivior PLC has announced the commencement of trading on the Nasdaq Global Select Market while retaining its premium listing on the London Stock Exchange. This dual listing, effective from June 9, will help increase exposure in the U.S. market, which Indivior considers a significant opportunity. CEO Mark Crossley emphasized the importance of this listing for raising awareness about substance use disorders and promoting treatment as a medical need. A campaign aimed at destigmatizing addiction will accompany the Nasdaq bell ringing event on June 14, which will feature patients and their families.
Read more →INDVIndivior Reaches Agreement with States' Attorneys General and District of Columbia to Resolve Antitrust Multi-District Litigation Claims Indivior PLC (LSE: INDV), a leading addiction treatment company, announced that its subsidiary, Indivior Inc. (the Company ), has reached an...
Indivior PLC announced a settlement agreement to resolve antitrust claims brought by the Attorneys General of 41 states and the District of Columbia related to the Suboxone Antitrust Litigation. The agreement involves a settlement payment of $102.5 million, which will reduce the previously established $290 million provision for the overall multi-district litigation. Once the agreement is approved by the court, Indivior aims to reinforce its commitment to helping patients with substance use disorders while addressing legacy litigation concerns.
Read more →INDVIndivior To Participate In Upcoming Investor Conferences Indivior PLC (LSE: INDV) today announced that it will participate in the following investor events: Jefferies Healthcare Conference – New York City,...
Indivior PLC has announced its participation in notable upcoming investor conferences, including the Jefferies Healthcare Conference in New York City and the Stifel European Healthcare Conference in Bordeaux, France. CEO Mark Crossley and CFO Ryan Preblick will host meetings and presentations aimed at engaging with investors. The company emphasized its commitment to addressing substance use disorders and expanding its product pipeline. These events are part of Indivior's strategy to increase its visibility and reinforce its position in the pharmaceutical industry.
Read more →INDVIndivior PLC Form 20-F Registration Statement for Additional US Listing Now Available; Trading on NASDAQ Expected to Commence on June 12th Indivior PLC (LSE: INDV) today announced that its registration statement on Form 20-F required for the additional U.S. listing of its ordinary shares ...
Indivior PLC has filed its Form 20-F registration statement, enabling its ordinary shares to be listed on NASDAQ starting June 12, 2023, pending SEC approval. This move aims to enhance its market presence while retaining its premium listing on the London Stock Exchange. Additionally, the current ADR program will terminate before the US listing, leading to a mandatory exchange of American depository shares for ordinary shares on a 1:1 basis. The statement also highlights various forward-looking risks that could impact the company's performance.
Read more →INDVIndivior Announces U.S. Food and Drug Administration Approval of OPVEE® (nalmefene) Nasal Spray, An Opioid Overdose Rescue Medicine for Natural and Synthetic Opioids Like Fentanyl Indivior PLC (LSE: INDV) today announced that the U.S. Food and Drug Administration (FDA) approved OPVEE® (nalmefene) nasal spray for the emergency...
Indivior PLC announced that the FDA has approved its OPVEE® (nalmefene) nasal spray for emergency treatment of opioid overdoses. The spray is designed for use in adults and pediatric patients aged 12 years and older, effectively reversing respiratory depression caused by natural and synthetic opioids, including fentanyl. The approval was bolstered by a pharmacodynamic study demonstrating its fast action and prolonged efficacy. OPVEE is expected to become available in the market by Q4 2023, with potential annual net revenue projected between $150 million and $250 million following its launch.
Read more →INDVIndivior Announces Q1 2023 Financial Results Indivior PLC (LSE: INDV) today announced its financial results for the period ending March 31, 2023. The earnings release, investor presentation and...
Indivior PLC announced its financial results for Q1 2023, highlighting ongoing initiatives in its business. The company is focused on treating substance use disorders and serious mental illnesses. Additionally, Indivior is working on expanding its pipeline of product candidates to address various chronic conditions. The earnings release and additional resources are available for investors and interested parties.
Read more →INDVIndivior To Participate In Bank of America Global Healthcare Conference 2023 Indivior PLC (LSE: INDV) today announced that it will participate in the following investor event: Bank of America Global Healthcare Conference 2023...
Indivior PLC announced its participation in the upcoming Bank of America Global Healthcare Conference 2023. The global pharmaceutical company aims to enhance awareness about its efforts in treating substance use disorders and related mental health conditions. Indivior is dedicated to providing access to evidence-based treatments and is expanding its portfolio to address various chronic conditions, including alcohol and cannabis use disorders. This event presents an opportunity for Indivior to connect with investors and stakeholders in the healthcare sector.
Read more →INDVIndivior Completes Acquisition of Opiant Pharmaceuticals, Inc. Indivior PLC (LSE: INDV) ( Indivior or the Company ) today announced that it has completed the acquisition of Opiant Pharmaceuticals, Inc....
Indivior PLC has completed the acquisition of Opiant Pharmaceuticals, enhancing its addiction treatment portfolio with Opiant's late-stage assets, including OPNT003, a potential treatment for opioid overdoses. The acquisition, valued at approximately $145 million, aims to address the ongoing U.S. opioid epidemic. Indivior anticipates that OPNT003 could generate substantial revenues after its launch, with further guidance expected in April 2023. The acquisition also supports Indivior's mission to provide comprehensive care for substance use disorders.
Read more →INDVFY 2022 Financial Results Announced Indivior PLC (LSE: INDV) today announced 2022 Full Year Results. The earnings release, investor presentation, and webcast are available at...
Indivior PLC has announced its full year financial results for 2022, highlighting its ongoing commitment to developing treatments for substance use disorders and serious mental illnesses. The company plans to discuss these results in a live webcast, emphasizing its efforts in providing evidence-based treatment across the globe. Indivior continues to strengthen its position in the market with a diverse pipeline aimed at expanding its product offerings.
Read more →INDVIndivior Announces First Patient Included in Aelis Farma's Phase 2b Study Assessing the Efficacy, Safety and Tolerability of AEF0117 in Treatment-Seeking Subjects With Moderate to Severe Cannabis Use Disorder Indivior PLC (LON: INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder...
SLOUGH, England and RICHMOND, Va. , June 1, 2022 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD). This follows less than a year after Indivior and Aelis Farma
Read more →INDVIndivior Presents New Data at the College on Problems of Drug Dependence (CPDD) 2021 Annual Conference Indivior PLC (LON: INDV) announces the presentation of new data from three posters and one late-breaking oral presentation at the College on Problems ...
RICHMOND, Va. , June 24, 2021 /PRNewswire/ -- Indivior PLC (LON: INDV) announces the presentation of new data from three posters and one late-breaking oral presentation at the College on Problems of Drug Dependence (CPDD) 83 rd Annual Scientific Virtual Meeting taking place June
Read more →INDVIndivior Extends Leadership Position In Substance Use Disorder Treatment With Exclusive Agreement For Leading Asset Targeting Cannabis-Related Disorders Indivior PLC, (LON: INDV) today announced that it is extending its leadership position in substance use disorder ( SUD ) treatment by expanding into...
RICHMOND, Va. , June 8, 2021 /PRNewswire/ -- Indivior PLC, (LON: INDV) today announced that it is extending its leadership position in substance use disorder ("SUD") treatment by expanding into the under treated cannabis-related disorders, including cannabis use disorder ("CUD")
Read more →INDVStudy Examining Impact of COVID-19 Pandemic on Opioid Use Disorder (OUD) Finds Greater Barriers to Care During Pandemic Indivior PLC (LON: INDV) today announced findings from a qualitative study examining the impact of COVID-19 on opioid use disorder (OUD) management...
RICHMOND, Va. , April 22, 2021 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced findings from a qualitative study examining the impact of COVID-19 on opioid use disorder (OUD) management and medication for opioid use disorder (MOUD) access in the U.S. which found that 85%
Read more →INDVIndivior Recognizes Drug and Alcohol Facts Week® 2021, developed by The National Institute on Drug Abuse (NIDA) March 22 through March 28, 2021 is National Drug and Alcohol Facts Week®, an annual, week-long, health observance developed by the National Institute ...
RICHMOND, Va. , March 23, 2021 /PRNewswire/ -- March 22 through March 28, 2021 is National Drug and Alcohol Facts Week®, an annual, week-long, health observance developed by the National Institute on Drug Abuse (NIDA) to raise awareness about substance abuse, including alcohol, a
Read more →INDVIndivior Announces Availability of Third Quarter and Nine Months 2020 Results Indivior PLC (LON: INDV) today announced that financial results for the third quarter and nine months period ended September 30, 2020, including the...
SLOUGH, England , and RICHMOND, Va. , Oct. 29, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that financial results for the third quarter and nine months period ended September 30, 2020 , including the press release and investor supplement, are now available on th
Read more →INDVIndivior Takes Strategic Alignment Actions Indivior PLC (LON: INDV) today announced that it is taking organizational and cost actions to better align its capabilities and resources with the...
SLOUGH, United Kingdom and RICHMOND, Virginia , Sept. 24, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it is taking organizational and cost actions to better align its capabilities and resources with the Group's strategic priorities. These actions further co
Read more →INDVIndivior First Half and Second Quarter 2020 Results Now Available; Conference Call With Leadership Today Indivior PLC (LON: INDV) today announced that its first half and second quarter 2020 results press release is now available via the London Stock...
SLOUGH, United Kingdom , and RICHMOND, Va. , July 30, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its first half and second quarter 2020 results press release is now available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investo
Read more →INDVIndivior Announces Agreement to Resolve Criminal Charges and Civil Complaints Related to SUBOXONE® Film Indivior PLC (LON: INDV) ( Indivior or the Company ) announced that it has reached an agreement with the United States Department of Justice...
SLOUGH, England and RICHMOND, Va. , July 24, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") announced that it has reached an agreement with the United States Department of Justice (Justice Department), the Federal Trade Commission ("FTC"), and U.S. st
Read more →INDVIndivior Q1 2020 Results Now Available; Conference Call With Leadership Today Indivior PLC (LON: INDV) today announced that its Q1 2020 press release is now available via the London Stock Exchange's Regulatory News Service...
SLOUGH, England and RICHMOND, Va. , May 14, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its Q1 2020 press release is now available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's website at www.i
Read more →INDVSUBLOCADE® Long-Term Safety Data Published in Journal of Clinical Psychopharmacology Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release) injection, for...
SLOUGH, England and RICHMOND, Va. , April 16, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the publication of long-term safety data for SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use (CIII). The manuscript entitled " Treating Opioid
Read more →INDVIndivior Full Year 2019 Results Now Available; Leadership Presentation Today Indivior PLC (LON: INDV) today announced that its full year 2019 press release is now available via the London Stock Exchange's Regulatory News...
SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 13, 2020 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its full year 2019 press release is now available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" section of the company's w
Read more →INDVVirginia Tech and Indivior Announce New Collaboration to Study Long-Term Recovery in People with Opioid Use Disorder Indivior PLC (LON: INDV) today announced a new research collaboration with Virginia Tech extending the RECOVER (Remission from Chronic Opioid...
SLOUGH, England and RICHMOND, Va , Dec. 10, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced a new research collaboration with Virginia Tech extending the RECOVER (Remission from Chronic Opioid Use-Studying Environmental and Socio-Economic Factors on Recovery) Study
Read more →INDVNew Analysis From One-Year Study of Monthly Buprenorphine Extended-Release Injections Showed Improved or Stable Patient-Centered Outcomes Indivior PLC (LON: INDV) announced today that new analysis from a 12-month investigation of monthly buprenorphine extended-release injections showed...
SLOUGH, England and RICHMOND, Va. , Dec. 2, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) announced today that new analysis from a 12-month investigation of monthly buprenorphine extended-release injections showed that study participants who were treated with SUBLOCADE® (buprenor
Read more →INDVAnnouncement of National Institutes of Health (NIH) Grant Award through the NIH Helping to End Addiction Long-term (HEAL) Initiative Indivior PLC (LON: INDV) announces that the National Institutes of Health (NIH) has granted Indivior's application entitled Clinical Evaluation of...
RICHMOND, Va. , Sept. 26, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) announces that the National Institutes of Health (NIH) has granted Indivior's application entitled " Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatme
Read more →INDVIndivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985m Indivior PLC (LON: INDV) today announced revised expectations for FY 2019 net revenue and net income following stronger than expected H1 2019 net...
SLOUGH, England and RICHMOND, Va. , July 11, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced revised expectations for FY 2019 net revenue and net income following stronger than expected H1 2019 net revenue performance. The primary driver has been the market share ou
Read more →INDVIndivior First Quarter 2019 Results Now Available; Conference Call With Leadership Today Indivior PLC (LON: INDV) today announced that its first quarter 2019 press release and investor supplement are now available via the London Stock...
SLOUGH, England and RICHMOND, Va. , May 2, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its first quarter 2019 press release and investor supplement are now available via the London Stock Exchange's Regulatory News Service (RNS) and on the "Investors" sectio
Read more →INDVStatement of Indivior on Grand Jury Indictment Indivior PLC (LON: INDV) issued the following statement today in response to an indictment returned by a federal grand jury in the Western District...
SLOUGH, United Kingdom and RICHMOND, Va. , April 9, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) issued the following statement today in response to an indictment returned by a federal grand jury in the Western District of Virginia : "We are extremely disappointed in this actio
Read more →INDVIndivior Announces Launch of PERSERIS™ (risperidone) for the Treatment of Schizophrenia in Adults Indivior PLC (LON: INDV) today announced the launch of once-monthly PERSERIS™ (risperidone) for extended-release injectable suspension in the United...
SLOUGH, England and RICHMOND, Va. , Feb. 27, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the launch of once-monthly PERSERIS ™ (risperidone) for extended-release injectable suspension in the United States . PERSERIS is approved by the U.S. Food and Drug Administ
Read more →INDVIndivior Announces Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film Authorized Generic Indivior PLC (LON: INDV) today announced that its U.S. affiliate, Indivior Inc., has launched an authorized generic version of SUBOXONE®...
SLOUGH, England and RICHMOND, Va. , Feb. 20, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its U.S. affiliate, Indivior Inc., has launched an authorized generic version of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in the U.S. The authorize
Read more →INDVIndivior Provides Legal and Trading Update; Confirms Launch of PERSERIS™ and Key Elements of Contingency Plan Indivior PLC (the Company ) with today's announcement and accompanying supplement published on its website (http://www.indivior.com) is: Providing...
SLOUGH, England , Dec. 18, 2018 /PRNewswire/ -- Indivior PLC (the "Company") with today's announcement and accompanying supplement published on its website ( http://www.indivior.com ) is: This announcement and the accompanying supplement substitutes for the Capital Markets Day t
Read more →INDVCourt of Appeals for the Federal Circuit Declines to Immediately Issue Mandate After Preliminary Injunction Ruling Indivior PLC (LON: INDV) ( Indivior or the Company ) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied Dr....
SLOUGH, England, Dec. 12, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied Dr. Reddy's Laboratories (DRL's) motion to immediately issue the mandate following the CA
Read more →INDVIndivior to Host Conference Call on December 18th; Previously-Scheduled Capital Markets Day to be Held in February 2019 Indivior PLC (LON: INDV) ( Indivior or the Company ) today announced that in light of the recent decision by the Court of Appeals for the Federal...
This conference call substitutes for the previously-scheduled December 5 th Capital Markets Day. The conference call will be accompanied by a press release itemizing the key points to be made on the conference call. Indivior will seek to host a rescheduled Capital Markets Day as
Read more →INDVIndivior Announces Health Canada Approval of SUBLOCADE⢠(Buprenorphine Extended-Release) Injection for Patients with Moderate to Severe Opioid Use Disorder Indivior PLC (LON: INDV) today announced that Health Canada has approved SUBLOCADETM (buprenorphine extended-release) injection for subcutaneous...
SUBLOCADE is the first and only once-monthly injectable buprenorphine formulation approved in Canada for the management of moderate to severe opioid use disorder SLOUGH, England and RICHMOND, Va. , Nov. 23, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that Healt
Read more →INDVCourt of Appeals for the Federal Circuit Lifts Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Indivior PLC (LON: INDV) ( Indivior or the Company ) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) vacated the...
SLOUGH, England , Nov. 21, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) vacated the preliminary injunction (PI) previously granted against Dr. Reddy's Laboratories (DRL) b
Read more →INDVPERSERIS™, the First Once-Monthly Risperidone-Containing Subcutaneous Long-Acting Injectable, Now Available in the U.S. for the Treatment of Schizophrenia in Adults Indivior PLC (LON: INDV) today announced that PERSERIS™ (risperidone) for extended-release injectable suspension is now available in the United...
SLOUGH, England and RICHMOND, Va. , Nov. 19, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that PERSERIS ™ (risperidone) for extended-release injectable suspension is now available in the United States . PERSERIS is approved by the U.S. Food and Drug Administratio
Read more →INDVIndivior Announces Upcoming Investor Events Indivior PLC (LON: INDV) today announced the following upcoming investor events: Stifel 2018 Healthcare Conference, New York City: On Tuesday,...
SLOUGH, United Kingdom and RICHMOND, Va. , Nov. 6, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the following upcoming investor events: Stifel 2018 Healthcare Conference, New York City : On Tuesday, November 13 th from 9:30 a.m. to 10:10 a.m. (local time) Shaun
Read more →INDVIndivior Announces Nine Month and Third Quarter 2018 Results Indivior PLC (LON: INDV) today announced that its financial results for the period ended September 30, 2018, including the earnings release and...
SLOUGH, United Kingdom and RICHMOND, Va. , Nov. 1, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that its financial results for the period ended September 30, 2018 , including the earnings release and investor supplement, are available on the Company's website at
Read more →INDVIndivior Provides Update on Key Business Drivers and Expectations Indivior PLC (LON: INDV) today is providing a further update on key business drivers and expectations related to: FY 2018 net revenue and net income...
SLOUGH, U.K. and RICHMOND, Va. , Sept. 26, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today is providing a further update on key business drivers and expectations related to: FY 2018 Guidance : Indivior today provided revised FY 2018 guidance of net revenue of $990 - $1,020
Read more →INDVIndivior Unable to Participate in Morgan Stanley Healthcare Conference Due to Adverse Weather Indivior PLC (LON: INDV) today announced that due to adverse weather expected from Hurricane Florence, the recently declared state of emergency in...
SLOUGH, England and RICHMOND, Va. , Sept. 12, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that due to adverse weather expected from Hurricane Florence, the recently declared state of emergency in Virginia and its likely impact on East Coast travel, the Company i
Read more →INDVIndivior Prepays $150 Million of Outstanding Debt Indivior PLC (LON: INDV) today announced that it has completed the prepayment of $150 million of its outstanding Term loan facilities. As a result,...
SLOUGH, England and RICHMOND, Va. , Sept. 10, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it has completed the prepayment of $150 million of its outstanding Term loan facilities. As a result, outstanding borrowing under the Term loan facilities is $333 mill
Read more →INDVIndivior Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Upheld Indivior PLC (LON: INDV) (Indivior or the Company) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied Dr....
SLOUGH, England , July 31, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) (Indivior or the Company) today announced that the U.S. Court of Appeals for the Federal Circuit (CAFC) has denied Dr. Reddy's Laboratories' (DRL's) motion for a stay of the July 13, 2018 preliminary injunct
Read more →INDVIndivior Announces H1 2018 Results Period to June 30th Q2 2018 $m Q2 2017 $m % ∆ Actual FX % ∆ Constant FX H1 2018 $m H1 2017 $m % ∆ Actual FX % ∆ Constant FX Net Revenue 268 288 -7 -8 ...
SLOUGH, England , July 25, 2018 /PRNewswire/ -- H1 2018 Financial Results H1 2018 Operating Highlights FY 2018 Financial Guidance withdrawn July 11th Shaun Thaxter , CEO of Indivior, Comment "While our base U.S. business has recently been impacted by known risks that have ma
Read more →INDVIndivior Is Granted Preliminary Injunction on Generic (buprenorphine and naloxone) Sublingual Film Indivior PLC (LON: INDV) ( Indivior or the Company ) today announced that the U.S. District Court for the District of New Jersey has granted a...
The U.S. District Court for the District of New Jersey has also ordered Indivior to post a bond to provide security to DRL should the court conclude at the end of patent litigation that the '305 patent is invalid and/or not infringed. The bond amount will be determined by the cou
Read more →INDVIndivior Sees FY 2018 Net Revenue and Adjusted Net Income Below Previous Expectations Indivior PLC (LON: INDV) ( Indivior or the Company ) today announced that its previous FY 2018 financial guidance (net revenue: $1,130m - $1,170m;...
SLOUGH, England, July 11, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that its previous FY 2018 financial guidance (net revenue: $1,130m - $1,170m ; adjusted net income: $280m - $320m ) is no longer valid based on recent US market d
Read more →INDVIndivior to Announce and Present Half Year 2018 Results on July 25th Indivior PLC (LON: INDV) today announced that it will release its half year 2018 results on July 25th at 7:00 a.m. London time (2:00 a.m. U.S. EDT)....
SLOUGH, England and RICHMOND, Va. , July 10, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it will release its half year 2018 results on July 25 th at 7:00 a.m. London time ( 2:00 a.m. U.S. EDT). The results will be available via the London Stock Exchange's R
Read more →INDVIndivior's Temporary Restraining Order is Extended Indivior PLC (LON: INDV) ( Indivior or the Company ) today announced that the U.S. District Court for the District of New Jersey heard Indivior's...
SLOUGH, England , June 28, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.S. District Court for the District of New Jersey heard Indivior's application for a preliminary injunction (PI) against Dr. Reddy's Laboratories (DRL)
Read more →INDVIndivior Is Granted Temporary Restraining Order Indivior PLC (LON: INDV) ( Indivior or the Company ) today announced that the U.S. District Court for the District of New Jersey has granted...
SLOUGH, England , June 15, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that the U.S. District Court for the District of New Jersey has granted Indivior a temporary restraining order (TRO) that compels Dr. Reddy's (DRL) to immediatel
Read more →INDVIndivior Responds to Generic SUBOXONE® Approvals and Dr. Reddy's Launch At-Risk Indivior PLC (LON: INDV) ( Indivior or the Company ) today announced that it is aware that, on 14 June 2018, the US FDA approved generic versions...
SLOUGH, England , June 15, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that it is aware that, on 14 June 2018 , the US FDA approved generic versions of SUBOXONE® Film from both Dr. Reddy's and Mylan, and that Dr. Reddy's subsequentl
Read more →INDVIndivior Receives Subpoena from California Department of Insurance Indivior PLC (LON: INDV) announced today that Indivior Inc., its wholly owned subsidiary, received a subpoena from the Office of the Insurance...
SLOUGH, England and RICHMOND, Va. , May 31, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) announced today that Indivior Inc., its wholly owned subsidiary, received a subpoena from the Office of the Insurance Commissioner for the California Department of Insurance ("CDI") on May 2
Read more →INDVIndivior Announces Regulatory Submission to Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence Indivior PLC (LON: INDV) today announced that it has filed a regulatory submission with Australia's Therapeutic Goods Administration (TGA) for...
SLOUGH, England and RICHMOND, Va. , May 25, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it has filed a regulatory submission with Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE™ (buprenorphine extended-release) injection, for subcutaneous
Read more →INDVIndivior's Mark Crossley to Participate in Jefferies 2018 Global Healthcare Conference on June 5th Indivior PLC (LON: INDV) today announced that Mark Crossley, CFO, will participate in Jefferies 2018 Global Healthcare Conference on Tuesday, June...
SLOUGH, England , May 24, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that Mark Crossley , CFO, will participate in Jefferies 2018 Global Healthcare Conference on Tuesday, June 5th, 2018 , at 8:30 a.m. local time, in New York City . Crossley will discuss Indivio
Read more →INDVIndivior Enters into Settlement with Par Pharmaceutical in Patent Infringement Case Indivior PLC (LON: INDV) ( Indivior or the Company ) today announced that its U.S. subsidiary, Indivior Inc., together with Aquestive Therapeutics, ...
SLOUGH, England , May 14, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that its U.S. subsidiary, Indivior Inc., together with Aquestive Therapeutics, Inc. (formerly known as Monosol Rx, LLC), entered into a settlement agreement with
Read more →INDVIndivior to Announce First Quarter 2018 Results on May 2nd and Host Conference Call Indivior PLC (LON: INDV) today announced that it will release its first quarter 2018 results on May 2nd at 12:00 p.m. London time (7:00 a.m. U.S....
SLOUGH, England and RICHMOND, Va. , April 11, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it will release its first quarter 2018 results on May 2 nd at 12:00 p.m. London time ( 7:00 a.m. U.S. Eastern). The results will be available via the London Stock Exch
Read more →INDVIndivior Enters Into an Exclusive Global License Agreement for C4X Discovery's Orexin-1 (OX1) Antagonist Program Indivior PLC ( Indivior ) (LON: INDV) today announced that its subsidiary Indivior UK Limited ( Indivior UK ) and C4X Discovery Holdings PLC ( C4X )...
SLOUGH, England and RICHMOND, Va. , March 29, 2018 /PRNewswire/ -- Indivior PLC ("Indivior") (LON: INDV) today announced that its subsidiary Indivior UK Limited ("Indivior UK") and C4X Discovery Holdings PLC ("C4X") (AIM: C4XD) entered into a license agreement whereby Indivior UK
Read more →INDVSUBLOCADE™ (Buprenorphine Extended-Release) is Now Available as First and Only Monthly Injectable Buprenorphine in the U.S. to Treat Patients with Moderate to Severe Opioid Use Disorder Indivior PLC (LON: INDV) today announced that SUBLOCADE™ (buprenorphine extended-release) injection, for subcutaneous use (CIII), is now available in ...
SLOUGH, England and RICHMOND, Va. , March 1, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that S UBLOCADE™ (buprenorphine extended-release) injection, for subcutaneous use (CIII), is now available in the United States . SUBLOCADE is approved by the U.S. Food and
Read more →INDVIndivior Files Complaints Asserting New SUBOXONE® Film Patent Against ANDA-filers Indivior PLC (LON: INDV) ( Indivior or the Company ) today announced that its U.S. subsidiary, Indivior Inc., has filed patent lawsuits against Dr. ...
SLOUGH, England , Feb. 8, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior" or the "Company") today announced that its U.S. subsidiary, Indivior Inc., has filed patent lawsuits against Dr. Reddy's, Actavis, Par, Alvogen and Teva for infringement of United States Patent No
Read more →INDVIndivior to Announce Full Year 2017 Results on February 15th Indivior PLC (LON: INDV) today announced that it will release its full year 2017 results on February 15th at 7:00 a.m. London time (2:00 a.m. U.S....
SLOUGH, England and RICHMOND, Va. , Jan. 19, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that it will release its full year 2017 results on February 15 th at 7:00 a.m. London time ( 2:00 a.m. U.S. EST). The results will be available via the London Stock Exchange
Read more →INDVIndivior's Shaun Thaxter to Present at the 36th Annual J.P. Morgan Healthcare Conference on January 11th Indivior PLC (LON: INDV) today announced that Shaun Thaxter, CEO, will present at the 36th Annual J.P. Morgan Healthcare Conference on January 11th,...
SLOUGH, England and RICHMOND, Va. , Jan. 4, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that Shaun Thaxter , CEO, will present at the 36 th Annual J.P. Morgan Healthcare Conference on January 11th, 2018 , at 8:30 a.m. local Pacific time ( 11:30 a.m. Eastern / 4:
Read more →INDVIndivior and Addex Enter Strategic Collaboration to Accelerate Development of GABA(B) PAMs for Addiction Disorder Treatments Indivior PLC (LON: INDV) ( Indivior ) today announced that Indivior UK Limited has entered into a strategic collaboration with Addex Pharma S.A., a...
SLOUGH, England and RICHMOND, Va. , Jan. 3, 2018 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior") today announced that Indivior UK Limited has entered into a strategic collaboration with Addex Pharma S.A., a wholly-owned subsidiary of Addex Therapeutics Ltd. (SIX: ADXN) ("Ad
Read more →INDVIndivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot Indivior PLC (LON: INDV) (the 'Company') today announces that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) ...
SLOUGH, England and RICHMOND, Va. , Dec. 12, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) (the 'Company') today announces that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for RBP-7000, an investigational, once-monthly injectable risper
Read more →INDVFDA Advisory Committees Recommend Approval of Indivior's RBP-6000 for the Treatment of Opioid Use Disorder Indivior PLC (LON: INDV) announced today that the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee ...
SLOUGH, U.K. and RICHMOND, Va. , Oct. 31, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) announced today that the Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 18 to 1 to rec
Read more →INDVIndivior PLC Announces FDA Acceptance with Priority Review Designation of RBP-6000 Buprenorphine Monthly Depot New Drug Application (NDA) for the Treatment of Opioid Use Disorder Indivior PLC (LON: INDV) today announces that the U.S. Food and Drug Administration (FDA) has accepted with a Priority Review designation the New...
SLOUGH, UK and RICHMOND, Va. , July 31, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) today announces that the U.S. Food and Drug Administration (FDA) has accepted with a Priority Review designation the New Drug Application (NDA) for RBP-6000, an investigational once-monthly inje
Read more →INDVIndivior PLC Presents Results from the Phase 3 Pivotal Study of RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder Indivior PLC (LON: INDV) today announced the presentation of results from its pivotal Phase 3 clinical trial (RB-US-13-0001) evaluating the efficacy...
SLOUGH, UK and RICHMOND, Va. , June 21, 2017 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced the presentation of results from its pivotal Phase 3 clinical trial (RB-US-13-0001) evaluating the efficacy and safety of RBP-6000, an investigational once-monthly injectable bup
Read more →INDVIndivior Applauds United States Surgeon General Dr. Vivek Murthy's Report on Substance Misuse and Substance Use Disorders Indivior PLC (LON: INDV) commends U.S. Surgeon General Dr. Vivek Murthy for the robust report released today titled, Facing Addiction in America:...
RICHMOND, Va. , Nov. 17, 2016 /PRNewswire/ -- Indivior PLC (LON: INDV) commends U.S. Surgeon General Dr. Vivek Murthy for the robust report released today titled, " Facing Addiction in America: The Surgeon General's Report on Alcohol, Drugs, and Health ." The U.S. Surgeon General
Read more →INDVIndivior Announces Positive Top-line Phase 3 Pivotal Study Results for RBP-6000 Buprenorphine Monthly Depot for the Treatment of Opioid Use Disorder There will be a conference call for analysts and investors, hosted by Shaun Thaxter, Chief Executive Officer and Christian Heidbreder, Chief...
SLOUGH, England , Aug. 16, 2016 /PRNewswire/ -- There will be a conference call for analysts and investors, hosted by Shaun Thaxter , Chief Executive Officer and Christian Heidbreder , Chief Scientific Officer, at 9am EDT 17 August 2016 (1400hrs UK time). Dial-in details are as
Read more →INDVIndivior Applauds Congressional Passage of Bipartisan Comprehensive Addiction & Recovery Act of 2016 (CARA) Indivior PLC (LON: INDV) commends the United States Senate and House of Representatives for their leadership in passing the Comprehensive Addiction & ...
RICHMOND, Va. , July 13, 2016 /PRNewswire/ -- Indivior PLC (LON: INDV) commends the United States Senate and House of Representatives for their leadership in passing the Comprehensive Addiction & Recovery Act of 2016 (CARA), S. 524. This bipartisan legislation signals a strong fe
Read more →INDVIndivior to Present New Data at ISPOR and ICOO that Assess Implications of Adherence, Healthcare Service Utilization and Costs in Opioid Use Disorder Indivior PLC (LON: INDV) will unveil new real-world data that assess relapse and Buprenorphine Medication-Assisted Treatment (B-MAT) adherence rates...
SLOUGH, England , May 20, 2016 /PRNewswire/ -- Indivior PLC (LON: INDV) will unveil new real-world data that assess relapse and Buprenorphine Medication-Assisted Treatment (B-MAT) adherence rates and healthcare service utilization costs in addition to optimal minimal length of tr
Read more →INDVIndivior Applauds Recent Momentum to Address Opioid Dependence and Overdose Epidemic Indivior PLC (LON: INDV) is encouraged by recent efforts at the federal, state and local levels of government to expand access to treatment options...
SLOUGH, England , Oct. 21, 2015 /PRNewswire/ -- Indivior PLC (LON: INDV) is encouraged by recent efforts at the federal, state and local levels of government to expand access to treatment options as a means to help address the growing opioid dependence and overdose epidemic. The
Read more →INDVIndivior PLC Responds to Court's Decision on Motion to Amend Indivior PLC (LON: INDV) today announced that the U.S. District Court for the District of Delaware granted the Company's motion to amend its...
SLOUGH, England , Oct. 12, 2015 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the U.S. District Court for the District of Delaware granted the Company's motion to amend its complaint to specifically refer to Teva Pharmaceuticals' Abbreviated New Drug Application (
Read more →INDVIndivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review Indivior PLC (LON: INDV) today announced that the New Drug Application (NDA) for naloxone nasal spray was accepted and received Priority Review by...
SLOUGH, England , July 29, 2015 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced that the New Drug Application (NDA) for naloxone nasal spray was accepted and received Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of opioid overdose. Thi
Read more →INDVIndivior PLC Announces Positive Top-line Results From Pivotal Phase 3 Trial of RBP-7000 in Schizophrenia Indivior PLC (LON: INDV) today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the ...
SLOUGH, England, May 5, 2015 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90
Read more →INDVToelating van INDIVIOR PLC tot de officiële lijst en tot verhandeling op de London Stock Exchange - NIET BESTEMD VOOR VRIJGAVE, PUBLICATIE OF DISTRIBUTIE (GEHEEL NOCH GEDEELTELIJK) IN, NAAR OF VANUIT ENIGE JURISDICTIE. DIT WEL DOEN VORMT EEN...
- NIET BESTEMD VOOR VRIJGAVE, PUBLICATIE OF DISTRIBUTIE (GEHEEL NOCH GEDEELTELIJK) IN, NAAR OF VANUIT ENIGE JURISDICTIE. DIT WEL DOEN VORMT EEN OVERTREDING VAN DE DESBETREFFENDE WETGEVING VAN EEN DERGELIJKE JURISDICTIE. DEZE AANKONDIGING IS GEEN PROSPECTUS MAAR EEN ADVERTENTIE, E
Read more →INDVLa société INDIVIOR PLC est admise à la cote officielle et à la spéculation sur la Bourse de Londres (LSE) - CE COMMUNIQUÉ NE DOIT PAS ÊTRE PUBLIÉ, DIFFUSÉ OU DISTRIBUÉ (EN TOTALITÉ OU EN PARTIE) DANS, À DESTINATION OU À PARTIR D'UNE JURIDICTION OÙ CELA...
- CE COMMUNIQUÉ NE DOIT PAS ÊTRE PUBLIÉ, DIFFUSÉ OU DISTRIBUÉ (EN TOTALITÉ OU EN PARTIE) DANS, À DESTINATION OU À PARTIR D'UNE JURIDICTION OÙ CELA CONSTITUERAIT UNE VIOLATION DE LA LÉGISLATION EN VIGUEUR. LE PRÉSENT COMMUNIQUÉ NE CONSTITUE PAS UN PROSPECTUS MAIS UNE ANNONCE À CAR
Read more →INDVINDIVIOR PLC é admitida na lista oficial para ser negociada na Bolsa de Valores de Londres - NÃO DEVE SER DIVULGADO, PUBLICADO OU DISTRIBUÍDO (NO TODO OU EM PARTE) EM, DENTRO OU A PARTIR DE NENHUMA JURISDIÇÃO EM QUE SE CONSTITUIRIA UMA...
- NÃO DEVE SER DIVULGADO, PUBLICADO OU DISTRIBUÍDO (NO TODO OU EM PARTE) EM, DENTRO OU A PARTIR DE NENHUMA JURISDIÇÃO EM QUE SE CONSTITUIRIA UMA VIOLAÇÃO DAS LEIS RELEVANTES DESSA JURISDIÇÃO. ESTE COMUNICADO NÃO É UM PROSPECTO, E SIM UM ANÚNCIO, E OS INVESTIDORES NÃO DEVEM ADQUIR
Read more →INDVINDIVIOR PLC zum offiziellen Verzeichnis und Handelsverkehr der London Stock Exchange zugelassen - WEDER TEILWEISE NOCH VOLLUMFÄNGLICH ZUR FREIGABE, PUBLIKATION ODER DISTRIBUTION IN, INNERHALB BZW. AUS RECHTSGEBIETEN BESTIMMT, IN DENEN EINE...
- WEDER TEILWEISE NOCH VOLLUMFÄNGLICH ZUR FREIGABE, PUBLIKATION ODER DISTRIBUTION IN, INNERHALB BZW. AUS RECHTSGEBIETEN BESTIMMT, IN DENEN EINE DERARTIGE HANDLUNG GEGEN DIE GÜLTIGE RECHTSPRECHUNG DES JEWEILIGEN GEBIETES VERSTOSSEN WÜRDE DIESE BEKANNTMACHUNG IST KEIN EMISSIONSPROS
Read more →INDVINDIVIOR PLC, admitida en el Listado Oficial para cotizar en la Bolsa de Valores de Londres Indivior PLC (LON: INDV) ( Indivior ) empezará a cotizar en el mercado principal de la Bolsa de Valores de Londres a las 8 a.m. GMT del día de hoy a...
SLOUGH, Reino Unido, 23 de diciembre de 2014 /PRNewswire/ -- Indivior PLC (LON: INDV) ("Indivior") empezará a cotizar en el mercado principal de la Bolsa de Valores de Londres a las 8 a.m. GMT del día de hoy a partir de la admisión de 718,577,616 de sus acciones ordinarias al seg
Read more →INDVINDIVIOR PLC Admission to the Official List and to Trading on the London Stock Exchange Indivior PLC (LON: INDV) ( Indivior ) will begin trading on the London Stock Exchange's main market at 8 a.m. GMT today following the admission of...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. THIS ANNOUNCEMENT IS NOT A PROSPECTUS BUT AN ADVERTISEMENT AND INVESTORS SHOULD NOT ACQUIRE
Read more →Competitive Position
How INDV ranks across every disease it competes inCompetitive Position is a premium feature
See how INDV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial